Robert H Howland

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5522375/publications.pdf

Version: 2024-02-01

275 papers

14,981 citations

51 h-index 22488 117 g-index

286 all docs

 $\begin{array}{c} 286 \\ \text{docs citations} \end{array}$

286 times ranked

12205 citing authors

#	Article	IF	Citations
1	A Brief, Fully Automated Neurocognitive Training Intervention Extends the Antidepressant Effect of a Single Ketamine Infusion. Biological Psychiatry, 2022, 91, S81.	0.7	O
2	International Consensus Based Review and Recommendations for Minimum Reporting Standards in Research on Transcutaneous Vagus Nerve Stimulation (Version 2020). Frontiers in Human Neuroscience, 2020, 14, 568051.	1.0	143
3	Cardiovascular Health and Cognitive Decline. JAMA - Journal of the American Medical Association, 2018, 320, 2483.	3.8	O
4	Cognitive outcome after ventral capsule/ventral striatum stimulation for treatment-resistant major depression. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 262-265.	0.9	23
5	Diet, atherosclerosis, and helmintic infection in Tsimane. Lancet, The, 2017, 390, 2034.	6.3	1
6	Diet, atherosclerosis, and helmintic infection in Tsimane. Lancet, The, 2017, 390, 2034-2035.	6.3	2
7	Use of Computer and Mobile Technologies in the Treatment of Depression. Archives of Psychiatric Nursing, 2017, 31, 311-318.	0.7	35
8	Pimavanserin: An Inverse Agonist Antipsychotic Drug. Journal of Psychosocial Nursing and Mental Health Services, 2016, 54, 21-24.	0.3	166
9	Antidepressant Drugs and the Risk of Intracranial Bleeding: Parsing an Observational Study. Journal of Psychosocial Nursing and Mental Health Services, 2016, 54, 21-24.	0.3	1
10	Oxazepam for the Treatment of Substance Abuse and Depression: Is it Appropriate?. Journal of Psychosocial Nursing and Mental Health Services, 2016, 54, 21-24.	0.3	1
11	Methylene Blue: The Long and Winding Road from Stain to Brain: Part 1. Journal of Psychosocial Nursing and Mental Health Services, 2016, 54, 21-24.	0.3	10
12	Methylene Blue: The Long and Winding Road From Stain to Brain: Part 2. Journal of Psychosocial Nursing and Mental Health Services, 2016, 54, 21-26.	0.3	4
13	Association Between Vitamin D Status and Cognitive Decline. JAMA Neurology, 2016, 73, 762.	4.5	1
14	Antidepressant, Antipsychotic, and Hallucinogen Drugs for the Treatment of Psychiatric Disorders: A Convergence at the Serotonin-2A Receptor. Journal of Psychosocial Nursing and Mental Health Services, 2016, 54, 21-24.	0.3	15
15	Trifluoperazine: A Sprightly Old Drug. Journal of Psychosocial Nursing and Mental Health Services, 2016, 54, 20-22.	0.3	9
16	Can Declining Rates of Dementia Be Explained by the Increased and Widespread Use of Psychotropic Medications?. Journal of Psychosocial Nursing and Mental Health Services, 2016, 54, 25-29.	0.3	4
17	Safety and Abuse Liability of Oxazepam: Is This Benzodiazepine Drug Underutilized?. Journal of Psychosocial Nursing and Mental Health Services, 2016, 54, 22-25.	0.3	6
18	Deprescribing to Reduce Medication Use: Will This Help Your Patient?. Journal of Psychosocial Nursing and Mental Health Services, 2016, 54, 21-24.	0.3	3

#	Article	IF	CITATIONS
19	Hey Mister Tambourine Man, Play a Drug for Me: Music as Medication. Journal of Psychosocial Nursing and Mental Health Services, 2016, 54, 23-27.	0.3	6
20	Safety and Efficacy of Synchronized Transcranial Magnetic Stimulation for the Treatment of Major Depressive Disorder. Brain Stimulation, 2015, 8, 404.	0.7	1
21	Buspirone: Back to the Future. Journal of Psychosocial Nursing and Mental Health Services, 2015, 53, 21-24.	0.3	40
22	Aspergillus, Angiogenesis, and Obesity: The Story Behind Beloranib. Journal of Psychosocial Nursing and Mental Health Services, 2015, 53, 13-16.	0.3	6
23	Deuterated Drugs. Journal of Psychosocial Nursing and Mental Health Services, 2015, 53, 13-6.	0.3	17
24	Psychiatric Medications and Sudden Cardiac Death: Putting the Risk in Perspective. Journal of Psychosocial Nursing and Mental Health Services, 2015, 53, 23-25.	0.3	16
25	"Evidence―and the Treatment of Alcohol Use Disorder. Journal of Psychosocial Nursing and Mental Health Services, 2015, 53, 11-14.	0.3	2
26	Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain. Journal of Psychosocial Nursing and Mental Health Services, 2015, 53, 19-22.	0.3	2
27	A Randomized Sham-Controlled Trial of Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Chronic Treatment-Resistant Depression. Biological Psychiatry, 2015, 78, 240-248.	0.7	415
28	Epidural Cortical Stimulation of the Left DLPFC Leads to Dose-Dependent Enhancement of Working Memory in Patients with MDD. Brain Stimulation, 2015, 8, 408.	0.7	0
29	Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression. Brain Stimulation, 2015, 8, 787-794.	0.7	145
30	Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: A CO-MED report. Journal of Affective Disorders, 2015, 174, 157-164.	2.0	19
31	Odds and Ends in Psychopharmacology From the Past 10 Years. Journal of Psychosocial Nursing and Mental Health Services, 2015, 53, 9-12.	0.3	1
32	Brexpiprazole: Another Multipurpose Antipsychotic Drug?. Journal of Psychosocial Nursing and Mental Health Services, 2015, 53, 23-25.	0.3	9
33	Do Psychiatric Medications Cause More Harm Than Good?. Journal of Psychosocial Nursing and Mental Health Services, 2015, 53, 15-19.	0.3	2
34	"l Want a New Drug― Exercise as a Pharmacological Therapy. Journal of Psychosocial Nursing and Mental Health Services, 2015, 53, 13-16.	0.3	3
35	Can a Bug in the Gut Act Like a Drug in the Brain?. Journal of Psychosocial Nursing and Mental Health Services, 2015, 53, 22-24.	0.3	1
36	Pharmacology of Dementing Disorders. , 2015, , .		0

#	Article	IF	CITATIONS
37	Psychopharmacology in the General Medical Setting. , 2015, , 95-118.		O
38	A Question About the Safety of Buprenorphine/Naloxone and Benzodiazepine Drugs. Journal of Psychosocial Nursing and Mental Health Services, 2015, 53, 11-14.	0.3	2
39	The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review. Current Neuropharmacology, 2014, 12, 444-461.	1.4	168
40	Peduncular Hallucinosis., 2014,, 848.		0
41	Quetiapine, QTc interval prolongation, and <i>torsade de pointes</i> : a review of case reports. Therapeutic Advances in Psychopharmacology, 2014, 4, 130-138.	1.2	51
42	QTc Prolongation and Haloperidol: Just How Risky is This Drug?. Psychosomatics, 2014, 55, 741-742.	2.5	4
43	Quetiapine and the Need for a Thorough QT/QTc Study. Journal of Clinical Psychopharmacology, 2014, 34, 3-6.	0.7	25
44	Ramelteon and the Prevention of Delirium. JAMA Psychiatry, 2014, 71, 1195.	6.0	0
45	The Striatum and Dopamine. JAMA Psychiatry, 2014, 71, 489.	6.0	8
46	Early-Life Milk and Late-Life Fracture. JAMA Pediatrics, 2014, 168, 683.	3.3	1
47	Mortality Risk of Mirtazapine. JAMA Psychiatry, 2014, 71, 585.	6.0	5
48	Vagus Nerve Stimulation. Current Behavioral Neuroscience Reports, 2014, 1, 64-73.	0.6	271
49	Thursday Abstracts. Biological Psychiatry, 2014, 75, S1-S134.	0.7	7
50	New Developments With Vagus Nerve Stimulation Therapy. Journal of Psychosocial Nursing and Mental Health Services, 2014, 52, 11-14.	0.3	20
51	Gabapentin: Can It Be Misused?. Journal of Psychosocial Nursing and Mental Health Services, 2014, 52, 12-15.	0.3	6
52	Gabapentin for Substance Use Disorders: Is it Safe and Appropriate?. Journal of Psychosocial Nursing and Mental Health Services, 2014, 52, 13-16.	0.3	10
53	Update on Deep Brain Stimulation. Journal of Psychosocial Nursing and Mental Health Services, 2014, 52, 23-26.	0.3	4
54	Delirium and Its Prevention with Melatonergic Drugs. Journal of Psychosocial Nursing and Mental Health Services, 2014, 52, 13-16.	0.3	5

#	Article	IF	CITATIONS
55	The Comparative Cardiac Effects of Haloperidol and Quetiapine: Parsing a Review. Journal of Psychosocial Nursing and Mental Health Services, 2014, 52, 23-26.	0.3	2
56	Atypical Antipsychotics Are Not All Alike: Side Effects and Risk Assessment. Journal of Psychosocial Nursing and Mental Health Services, 2014, 52, 13-15.	0.3	4
57	Suvorexant: A Novel Therapy for the Treatment of Insomnia. Journal of Psychosocial Nursing and Mental Health Services, 2014, 52, 23-26.	0.3	2
58	Pharmacogenetic Testing in Psychiatry: Not (Quite) Ready for Primetime. Journal of Psychosocial Nursing and Mental Health Services, 2014, 52, 13-16.	0.3	8
59	A Proposed System for Classifying Psychotropic Drugs. Journal of Psychosocial Nursing and Mental Health Services, 2014, 52, 13-15.	0.3	4
60	Down the Hatch: Is Prescribing Medication Really That Simple?. Journal of Psychosocial Nursing and Mental Health Services, 2014, 52, 13-16.	0.3	10
61	Psychotropic Medication Use:What Will It Do To My Liver?. Journal of Psychosocial Nursing and Mental Health Services, 2014, 52, 23-26.	0.3	8
62	Multidisciplinary Treatments and Medications for Depressive Disorders and Comorbidity. , 2014, , .		0
63	New developments with vagus nerve stimulation therapy. Journal of Psychosocial Nursing and Mental Health Services, 2014, 52, 11-4.	0.3	10
64	The Economic Burden of Treatment-Resistant Depression. Clinical Therapeutics, 2013, 35, 512-522.	1.1	110
65	The Reply. American Journal of Medicine, 2013, 126, e23.	0.6	0
66	Editorial: Deep brain stimulation and aggression. Journal of Neurosurgery, 2013, 119, 273-276.	0.9	2
67	Escitalopram and QTc prolongation. Journal of Psychiatry and Neuroscience, 2013, 38, E11-E11.	1.4	18
68	Methadone, QTc interval prolongation and <i>torsade de pointes</i> : Case reports offer the best understanding of this problem. Therapeutic Advances in Psychopharmacology, 2013, 3, 219-232.	1.2	30
69	Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED Trial Report. Psychological Medicine, 2013, 43, 945-960.	2.7	45
70	A "Glucose Eater―Drug as a Therapeutic Agent in Psychiatry. Journal of Psychosocial Nursing and Mental Health Services, 2013, 51, 13-16.	0.3	6
71	Concern for Truth: Driving Defensively When Confronting a Zombie Epidemic. Journal of Psychosocial Nursing and Mental Health Services, 2013, 51, 9-12.	0.3	1
72	Ketamine for the Treatment of Depression. Journal of Psychosocial Nursing and Mental Health Services, 2013, 51, 11-14.	0.3	14

#	Article	IF	CITATIONS
73	Antidepressant Medication and Pregnancy: Time for Randomized Controlled Trials. Journal of Psychosocial Nursing and Mental Health Services, 2013, 51, 11-14.	0.3	4
74	Therapies for Obesity and Medication-Associated Weight Gain. Journal of Psychosocial Nursing and Mental Health Services, 2013, 51, 13-16.	0.3	5
7 5	Mifepristone as a Therapeutic Agent in Psychiatry. Journal of Psychosocial Nursing and Mental Health Services, 2013, 51, 11-14.	0.3	24
76	More on Antidepressant Drugs and Infectious Disease. Journal of Psychosocial Nursing and Mental Health Services, 2013, 51, 11-13.	0.3	4
77	Gabapentin for the Treatment of Substance Use Disorders. Journal of Psychosocial Nursing and Mental Health Services, 2013, 51, 11-14.	0.3	10
78	Quantitative Electroencephalogram Biomarkers for Predicting Likelihood and Speed of Achieving Sustained Remission in Major Depression. Journal of Clinical Psychiatry, 2013, 74, 51-56.	1.1	26
79	Diagnostic Classification Past, Present, and Future: Implications for Pharmacotherapy. Journal of Psychosocial Nursing and Mental Health Services, 2013, 51, 13-16.	0.3	2
80	Antidepressant Drugs and Infectious Disease. Journal of Psychosocial Nursing and Mental Health Services, 2013, 51, 11-14.	0.3	0
81	Antidepressant drugs and infectious disease. Journal of Psychosocial Nursing and Mental Health Services, 2013, 51, 11-4.	0.3	20
82	Dietary Supplement Drug Therapies for Depression. Journal of Psychosocial Nursing and Mental Health Services, 2012, 50, 13-16.	0.3	11
83	Letters to the Editor. Journal of the American Veterinary Medical Association, 2012, 241, 417-419.	0.2	1
84	The Use of Dopaminergic and Stimulant Drugs for the Treatment of Depression. Journal of Psychosocial Nursing and Mental Health Services, 2012, 50, 11-14.	0.3	24
85	Novel melatonin-based treatments for major depression. Lancet, The, 2012, 379, 215-216.	6.3	9
86	Citalopram, QTc Interval Prolongation, and Torsade de Pointes. How Should We Apply the Recent FDA Ruling?. American Journal of Medicine, 2012, 125, 859-868.	0.6	260
87	EFFECT OF CONCURRENT SUBSTANCE USE DISORDER ON THE EFFECTIVENESS OF SINGLE AND COMBINATION ANTIDEPRESSANT MEDICATIONS FOR THE TREATMENT OF MAJOR DEPRESSION: AN EXPLORATORY ANALYSIS OF A SINGLE-BLIND RANDOMIZED TRIAL. Depression and Anxiety, 2012, 29, 111-122.	2.0	15
88	Now Take a Deep Breath: Inhaled Loxapine for the Treatment of Acute Agitation. Journal of Psychosocial Nursing and Mental Health Services, 2012, 50, 16-18.	0.3	1
89	A Question About the Potential Cardiac Toxicity of Escitalopram. Journal of Psychosocial Nursing and Mental Health Services, 2012, 50, 17-20.	0.3	7
90	Baclofen for the Treatment of Alcohol Dependence. Journal of Psychosocial Nursing and Mental Health Services, 2012, 50, 11-14.	0.3	7

#	Article	IF	Citations
91	Where Are We Today with Personalized Medicine?. Journal of Psychosocial Nursing and Mental Health Services, 2012, 50, 11-13.	0.3	8
92	Future Prospects for Pharmacogenetics in the Quest for Personalized Medicine. Journal of Psychosocial Nursing and Mental Health Services, 2012, 50, 13-16.	0.3	8
93	The Impact of Chronic Depression on Acute and Long-Term Outcomes in a Randomized Trial Comparing Selective Serotonin Reuptake Inhibitor Monotherapy Versus Each of 2 Different Antidepressant Medication Combinations. Journal of Clinical Psychiatry, 2012, 73, 967-976.	1.1	25
94	Effective Medication Management. Journal of Psychosocial Nursing and Mental Health Services, 2012, 50, 13-15.	0.3	1
95	The Challenges of Clinical Psychopharmacological Management. Journal of Psychosocial Nursing and Mental Health Services, 2012, 50, 17-20.	0.3	1
96	Questions to Ask When Selecting Medication. Journal of Psychosocial Nursing and Mental Health Services, 2012, 50, 13-15.	0.3	4
97	Off-Label Medication Use. Journal of Psychosocial Nursing and Mental Health Services, 2012, 50, 11-13.	0.3	5
98	Thursday Abstracts. Biological Psychiatry, 2011, 69, 1-98.	0.7	3
99	A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression. Drug Safety, 2011, 34, 709-731.	1.4	54
100	Publication Bias and Outcome Reporting Bias: Agomelatine as a Case Example. Journal of Psychosocial Nursing and Mental Health Services, 2011, 49, 11-14.	0.3	24
101	Vitamin D and Depression. Journal of Psychosocial Nursing and Mental Health Services, 2011, 49, 15-18.	0.3	35
102	A Critical Evaluation of the Cardiac Toxicity of Citalopram: Part 1. Journal of Psychosocial Nursing and Mental Health Services, 2011, 49, 13-16.	0.3	51
103	Epidural Cortical Stimulation of the Left Dorsolateral Prefrontal Cortex for Refractory Major Depressive Disorder. Neurosurgery, 2011, 69, 1015-1029.	0.6	65
104	The treatment of minor depression with St. Johnâ∈™s Wort or citalopram: Failure to show benefit over placebo. Journal of Psychiatric Research, 2011, 45, 931-941.	1.5	48
105	Sleep Interventions for the Treatment of Depression. Journal of Psychosocial Nursing and Mental Health Services, 2011, 49, 17-20.	0.3	19
106	Vilazodone. Journal of Psychosocial Nursing and Mental Health Services, 2011, 49, 19-22.	0.3	10
107	Update on Newer Antipsychotic Drugs. Journal of Psychosocial Nursing and Mental Health Services, 2011, 49, 13-15.	0.3	8
108	Alternative Drug Therapies for Dementia. Journal of Psychosocial Nursing and Mental Health Services, 2011, 49, 17-20.	0.3	9

#	Article	IF	Citations
109	Drug Therapies for Tardive Dyskinesia: Part 2. Journal of Psychosocial Nursing and Mental Health Services, 2011, 49, 17-20.	0.3	7
110	What You See Depends on Where You're Looking and How You Look at It: Publication Bias and Outcome Reporting Bias. Journal of Psychosocial Nursing and Mental Health Services, 2011, 49, 13-15.	0.3	8
111	Understanding and Assessing Adverse Drug Reactions. Journal of Psychosocial Nursing and Mental Health Services, 2011, 49, 13-15.	0.3	4
112	A Critical Evaluation of the Cardiac Toxicity of Citalopram: Part 2. Journal of Psychosocial Nursing and Mental Health Services, 2011, 49, 13-16.	0.3	20
113	Drug Therapies for Tardive Dyskinesia: Part 1. Journal of Psychosocial Nursing and Mental Health Services, 2011, 49, 13-16.	0.3	16
114	The emerging use of technology for the treatment of depression and other neuropsychiatric disorders. Annals of Clinical Psychiatry, 2011, 23, 48-62.	0.6	35
115	Peduncular hallucinosis. Clinical Schizophrenia and Related Psychoses, 2011, 5, 106-7; author reply 107.	1.4	2
116	Therapeutic Armamentarium for Treating Depression. Postgraduate Medicine, 2010, 122, 66-93.	0.9	12
117	Pharmacotherapy for Insomnia. Sleep Medicine Clinics, 2010, 5, 529-539.	1.2	12
118	Use of Endocrine Hormones for Treating Depression. Journal of Psychosocial Nursing and Mental Health Services, 2010, 48, 13-16.	0.3	23
119	Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. Drug and Alcohol Dependence, 2010, 107, 161-170.	1.6	71
120	Deficits in Psychological Wellâ€Being and Qualityâ€ofâ€Life in Minor Depression: Implications for DSMâ€V. CNS Neuroscience and Therapeutics, 2010, 16, 208-216.	1.9	41
121	Evaluating the Bioavailability and Bioequivalence of Generic Medications. Journal of Psychosocial Nursing and Mental Health Services, 2010, 48, 13-16.	0.3	8
122	When Is a "Generic―Medication not Really a Generic? Confusion About Medication Products Containing the Same Active Ingredient. Journal of Psychosocial Nursing and Mental Health Services, 2010, 48, 13-16.	0.3	3
123	Are Generic Medications Safe and Effective?. Journal of Psychosocial Nursing and Mental Health Services, 2010, 48, 13-16.	0.3	11
124	Drug Therapies for Cognitive Impairment and Dementia. Journal of Psychosocial Nursing and Mental Health Services, 2010, 48, 11-14.	0.3	10
125	The Diverse Clinical Uses of Opioid Receptor Drugs. Journal of Psychosocial Nursing and Mental Health Services, 2010, 48, 11-14.	0.3	3
126	Potential Adverse Effects of Discontinuing Psychotropic Drugs-Part 1: Adrenergic, Cholinergic, and Histamine Drugs. Journal of Psychosocial Nursing and Mental Health Services, 2010, 48, 11-14.	0.3	10

#	Article	IF	Citations
127	Potential Adverse Effects of Discontinuing Psychotropic Drugs. Journal of Psychosocial Nursing and Mental Health Services, 2010, 48, 9-12.	0.3	23
128	Potential Adverse Effects of Discontinuing Psychotropic Drugs. Journal of Psychosocial Nursing and Mental Health Services, 2010, 48, 11-14.	0.3	13
129	Potential Adverse Effects of Discontinuing Psychotropic Drugs. Journal of Psychosocial Nursing and Mental Health Services, 2010, 48, 11-14.	0.3	16
130	Serendipity and Psychopharmacology. Journal of Psychosocial Nursing and Mental Health Services, 2010, 48, 9-12.	0.3	7
131	Update on St. John's Wort. Journal of Psychosocial Nursing and Mental Health Services, 2010, 48, 20-24.	0.3	7
132	News. Journal of Psychosocial Nursing and Mental Health Services, 2010, 48, 10-46.	0.3	0
133	Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults. Neuropsychiatric Disease and Treatment, 2009, 5, 563.	1.0	28
134	An Overview of Seasonal Affective Disorder and its Treatment Options. Physician and Sportsmedicine, 2009, 37, 104-115.	1.0	27
135	Concurrent anxiety and substance use disorders among outpatients with major depression: Clinical features and effect on treatment outcome. Drug and Alcohol Dependence, 2009, 99, 248-260.	1.6	124
136	Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Research, 2009, 169, 132-138.	1.7	109
137	Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: Results of the BRITE-MD study. Psychiatry Research, 2009, 169, 124-131.	1.7	162
138	Pharmacogenetics and Pharmacovigilance. Drug Safety, 2009, 32, 265-270.	1.4	7
139	Cognitive Behavioral Analysis System of Psychotherapy and Brief Supportive Psychotherapy for Augmentation of Antidepressant Nonresponse in Chronic Depression <subtitle>The REVAMP Trial</subtitle> <alt-title>Augmentation With CBASP and BSP for Depression</alt-title> . Archives of General Psychiatry, 2009, 66, 1178.	13.8	189
140	A Double-blind Randomized Controlled Trial of Olanzapine Plus Sertraline vs Olanzapine Plus Placebo for Psychotic Depression. Archives of General Psychiatry, 2009, 66, 838.	13.8	188
141	Somatic Therapies for Seasonal Affective Disorder. Journal of Psychosocial Nursing and Mental Health Services, 2009, 47, 17-20.	0.3	11
142	What Should Patients Be Told About Their Medications?. Journal of Psychosocial Nursing and Mental Health Services, 2009, 47, 17-20.	0.3	3
143	Evaluating the Safety of Medications During Pregnancy and Lactation. Journal of Psychosocial Nursing and Mental Health Services, 2009, 47, 19-22.	0.3	7
144	Prescribing Psychotropic Medications During Pregnancy and Lactation: Principles and Guidelines. Journal of Psychosocial Nursing and Mental Health Services, 2009, 47, 19-23.	0.3	9

#	Article	IF	Citations
145	Categorizing the Safety of Medications During Pregnancy and Lactation. Journal of Psychosocial Nursing and Mental Health Services, 2009, 47, 17-20.	0.3	11
146	The Antidepressant Effects of Anticholinergic Drugs. Journal of Psychosocial Nursing and Mental Health Services, 2009, 47, 17-20.	0.3	23
147	Understanding Chirality and Stereochemistry: Three-Dimensional Psychopharmacology. Journal of Psychosocial Nursing and Mental Health Services, 2009, 47, 15-18.	0.3	3
148	Clinical Implications of Chirality and Stereochemistry in Psychopharmacology. Journal of Psychosocial Nursing and Mental Health Services, 2009, 47, 17-21.	0.3	8
149	Medication Holidays. Journal of Psychosocial Nursing and Mental Health Services, 2009, 47, 15-18.	0.3	17
150	Prescribing Psychotropic Medications for Elderly Patients. Journal of Psychosocial Nursing and Mental Health Services, 2009, 47, 17-20.	0.3	10
151	What Makes a Generic Medication Generic?. Journal of Psychosocial Nursing and Mental Health Services, 2009, 47, 17-20.	0.3	9
152	Using Computers and the Internet for Psychiatric Nursing Intervention. Journal of Psychosocial Nursing and Mental Health Services, 2009, 47, 13-14.	0.3	1
153	Economic Anxiety. Journal of Psychosocial Nursing and Mental Health Services, 2009, 47, 13-14.	0.3	0
154	Borderline Personality Disorder: Inpatient Psychiatric Nursing Management. Journal of Psychosocial Nursing and Mental Health Services, 2009, 47, 13-14.	0.3	1
155	Adolescent Depression: Assessment and Treatment. Journal of Psychosocial Nursing and Mental Health Services, 2009, 47, 11-12.	0.3	1
156	Weight Gain with Atypical Antipsychotic Drugs in Bipolar Disorder: Nursing Management. Journal of Psychosocial Nursing and Mental Health Services, 2009, 47, 11-12.	0.3	2
157	Effects of Aging on Pharmacokinetic and Pharmacodynamic Drug Processes. Journal of Psychosocial Nursing and Mental Health Services, 2009, 47, 15-18.	0.3	11
158	Caregivers of Loved Ones with Alzheimer's Disease: Nursing Care for the Caregivers. Journal of Psychosocial Nursing and Mental Health Services, 2009, 47, 13-14.	0.3	0
159	A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders. Brain Stimulation, 2008, 1, 112-121.	0.7	161
160	Chronic forms of major depression are still undertreated in the 21st century: Systematic assessment of 801 patients presenting for treatment. Journal of Affective Disorders, 2008, 110, 55-61.	2.0	68
161	Clinical Features and Functioning of Patients with Minor Depression. Psychotherapy and Psychosomatics, 2008, 77, 384-389.	4.0	53
162	Difference in Treatment Outcome in Outpatients With Anxious Versus Nonanxious Depression: A STAR*D Report. American Journal of Psychiatry, 2008, 165, 342-351.	4.0	741

#	Article	IF	CITATIONS
163	Factors Predicting Reduced Antidepressant Response: Experience with the SNRI Duloxetine in Patients with Major Depression. Annals of Clinical Psychiatry, 2008, 20, 209-218.	0.6	49
164	Commentary: The Need to Guard Against Pharmaceutical Industry Influence. Psychiatric Services, 2008, 59, 566-566.	1.1	0
165	Limitations of Evidence in the Practice of Evidence-based Medicine. Psychiatric Annals, 2008, 38, .	0.1	3
166	Medication Adherence. Psychiatric Annals, 2008, 38, .	0.1	3
167	How Are Drugs Approved? Part 1: the Evolution of the Food and Drug Administration. Journal of Psychosocial Nursing and Mental Health Services, 2008, 46, 15-19.	0.3	4
168	How Are Drugs Approved? Part 2: Ethical Foundations of Clinical Research. Journal of Psychosocial Nursing and Mental Health Services, 2008, 46, 15-20.	0.3	3
169	Understanding the Placebo Effect-Part 1: Placebo Use in Clinical Trials. Journal of Psychosocial Nursing and Mental Health Services, 2008, 46, 17-20.	0.3	10
170	Understanding the Placebo Effect-Part 2: Underlying Psychological & Neurobiological Processes. Journal of Psychosocial Nursing and Mental Health Services, 2008, 46, 15-18.	0.3	6
171	Sequenced Treatment Alternatives to Relieve Depression (STAR*D)Part 1: Study Design. Journal of Psychosocial Nursing and Mental Health Services, 2008, 46, 21-24.	0.3	34
172	Sequenced Treatment Alternatives to Relieve Depression (STAR*D)-Part 2: Study Outcomes. Journal of Psychosocial Nursing and Mental Health Services, 2008, 46, 21-24.	0.3	83
173	Risks and Benefits of Antipsychotic Drugs in Elderly Patients with Dementia. Journal of Psychosocial Nursing and Mental Health Services, 2008, 46, 19-23.	0.3	10
174	Understanding the Clinical Profile of a Drug on the Basis of Its Pharmacology: Mirtazapine as an Example. Journal of Psychosocial Nursing and Mental Health Services, 2008, 46, 19-23.	0.3	5
175	Does the Duration of Index Episode Affect the Treatment Outcome of Major Depressive Disorder?. Journal of Clinical Psychiatry, 2008, 69, 1246-1256.	1.1	39
176	Antidepressants and Suicide: Putting the Risk in Perspective. Psychiatric Annals, 2008, 38, .	0.1	0
177	How Are Drugs Approved? Part 3. the Stages of Drug Development. Journal of Psychosocial Nursing and Mental Health Services, 2008, 46, 17-20.	0.3	2
178	Neurosurgical Approaches to Therapeutic Brain Stimulation For Treatment-Resistant Depression. Journal of Psychosocial Nursing and Mental Health Services, 2008, 46, 15-19.	0.3	2
179	Pharmacotherapy for Psychotropic Drug-Related Weight Gain. Journal of Psychosocial Nursing and Mental Health Services, 2008, 46, 15-18.	0.3	0
180	Lisdexamfetamine: A Prodrug Stimulant for ADHD. Journal of Psychosocial Nursing and Mental Health Services, 2008, 46, 19-22.	0.3	17

#	Article	IF	Citations
181	How are drugs approved? Part 3. The stages of drug development. Journal of Psychosocial Nursing and Mental Health Services, 2008, 46, 17-20.	0.3	1
182	Commentary: The Need to Guard Against Pharmaceutical Industry Influence. Psychiatric Services, 2008, 59, 566-566.	1.1	0
183	Maximizing the Adequacy of Medication Treatment in Controlled Trials and Clinical Practice: STAR*D Measurement-Based Care. Neuropsychopharmacology, 2007, 32, 2479-2489.	2.8	135
184	Predictors of Attrition During Initial (Citalopram) Treatment for Depression: A STAR*D Report. American Journal of Psychiatry, 2007, 164, 1189-1197.	4.0	129
185	Feasibility Study of the Safety and Effectiveness of an Implantable Cortical Stimulation System for Subjects with Major Depression. Neurosurgery, 2007, 61, 215.	0.6	4
186	Managing Common Side Effects of SSRIs. Journal of Psychosocial Nursing and Mental Health Services, 2007, 45, 15-18.	0.3	6
187	Unusual and Serious Adverse Effects of SSRIs: Recognition and Management. Journal of Psychosocial Nursing and Mental Health Services, 2007, 45, 15-18.	0.3	4
188	Paliperidone Extended-Release Tablets: A New Atypical Antipsychotic. Journal of Psychosocial Nursing and Mental Health Services, 2007, 45, 15-18.	0.3	7
189	Pharmacotherapy in Personality Disorders. Journal of Psychosocial Nursing and Mental Health Services, 2007, 45, 15-19.	0.3	6
190	Lithium: Underappreciated and Underused?. Journal of Psychosocial Nursing and Mental Health Services, 2007, 45, 13-17.	0.3	6
191	Limitations of Evidence in the Practice of Evidence-Based Medicine. Journal of Psychosocial Nursing and Mental Health Services, 2007, 45, 13-16.	0.3	10
192	Agomelatine: A Novel Atypical Antidepressant. Journal of Psychosocial Nursing and Mental Health Services, 2007, 45, 13-17.	0.3	7
193	Glutamate-Modulating Drugs and the Treatment of Mental Disorders. Journal of Psychosocial Nursing and Mental Health Services, 2007, 45, 11-14.	0.3	7
194	Serzone Semantics. Journal of Psychosocial Nursing and Mental Health Services, 2007, 45, 13.	0.3	18
195	Antidepressants and Suicide: Putting the Risk in Perspective. Journal of Psychosocial Nursing and Mental Health Services, 2007, 45, 15-19.	0.3	3
196	Medication Adherence. Journal of Psychosocial Nursing and Mental Health Services, 2007, 45, 15-19.	0.3	19
197	Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression. New England Journal of Medicine, 2006, 354, 1231-1242.	13.9	934
198	Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice. American Journal of Psychiatry, 2006, 163, 28-40.	4.0	3,206

#	Article	IF	CITATIONS
199	Medication Augmentation after the Failure of SSRIs for Depression. New England Journal of Medicine, 2006, 354, 1243-1252.	13.9	897
200	Personalized Drug Therapy with Pharmacogeneticsâ€"Part 1: Pharmacokinetics. Journal of Psychosocial Nursing and Mental Health Services, 2006, 44, 13-16.	0.3	7
201	Personalized Drug Therapy with Pharmacogenetics—Part 2: Pharmadynamics. Journal of Psychosocial Nursing and Mental Health Services, 2006, 44, 13-16.	0.3	2
202	MAOI Antidepressant Drugs. Journal of Psychosocial Nursing and Mental Health Services, 2006, 44, 9-12.	0.3	7
203	Transdermal Selegiline: A Novel MAOI Formulation for Depression. Journal of Psychosocial Nursing and Mental Health Services, 2006, 44, 9-12.	0.3	7
204	What is Vagus Nerve Stimulation?. Journal of Psychosocial Nursing and Mental Health Services, 2006, 44, 11-14.	0.3	3
205	Vagus Nerve Stimulation for Depression and Other Neuropsychiatric Disorders. Journal of Psychosocial Nursing and Mental Health Services, 2006, 44, 11-14.	0.3	2
206	Electroencephalography Technology for Predicting Response to Antidepressant Medications. Journal of Psychosocial Nursing and Mental Health Services, 2006, 44, 11-14.	0.3	3
207	Pharmacotherapy Strategies for Treatment-Resistant Depression. Journal of Psychosocial Nursing and Mental Health Services, 2006, 44, 11-14.	0.3	4
208	Principles & Practice of Polypharmacotherapy. Journal of Psychosocial Nursing and Mental Health Services, 2006, 44, 13-16.	0.3	1
209	Challenges in the Diagnosis and Treatment of Bipolar Depressionâ€"Part 1: Assessment. Journal of Psychosocial Nursing and Mental Health Services, 2006, 44, 9-12.	0.3	1
210	Challenges in the Diagnosis and Treatment of Bipolar Depression—Part 2: Treatment Options. Journal of Psychosocial Nursing and Mental Health Services, 2006, 44, 9-12.	0.3	1
211	Pharmacotherapy for Psychotic Depression. Journal of Psychosocial Nursing and Mental Health Services, 2006, 44, 13-17.	0.3	5
212	Factors associated with chronic depressive episodes: a preliminary report from the STAR-D project. Acta Psychiatrica Scandinavica, 2005, 112, 425-433.	2.2	157
213	Chronic Depression. Archives of General Psychiatry, 2005, 62, 513.	13.8	139
214	Effects of 12 Months of Vagus Nerve Stimulation in Treatment-Resistant Depression: A Naturalistic Study. Biological Psychiatry, 2005, 58, 355-363.	0.7	345
215	Vagus Nerve Stimulation for Treatment-Resistant Depression: A Randomized, Controlled Acute Phase Trial. Biological Psychiatry, 2005, 58, 347-354.	0.7	542
216	A One-Year Comparison of Vagus Nerve Stimulation with Treatment as Usual for Treatment-Resistant Depression. Biological Psychiatry, 2005, 58, 364-373.	0.7	319

#	Article	IF	Citations
217	Therapeutic Brain Stimulation for Mental Disorders. Journal of Psychosocial Nursing and Mental Health Services, 2005, 43, 16-19.	0.3	2
218	Pharmacotherapy for Insomnia. Journal of Psychosocial Nursing and Mental Health Services, 2005, 43, 13-16.	0.3	2
219	Herbal Therapies. Journal of Psychosocial Nursing and Mental Health Services, 2005, 43, 16-19.	0.3	0
220	Anticonvulsant Drug Therapies. Journal of Psychosocial Nursing and Mental Health Services, 2005, 43, 17-20.	0.3	0
221	Use of Atypical Antipsychotics in Children & Adolescents. Journal of Psychosocial Nursing and Mental Health Services, 2005, 43, 15-18.	0.3	0
222	Atypical Antipsychotics: Special Formulations for Acute Agitation. Journal of Psychosocial Nursing and Mental Health Services, 2005, 43, 14-17.	0.3	0
223	Herbal therapies. Journal of Psychosocial Nursing and Mental Health Services, 2005, 43, 16-9.	0.3	0
224	Herbal therapies. Clinics in Geriatric Medicine, 2004, 20, 237-257.	1.0	13
225	Randomized, Placebo-Controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biological Psychiatry, 2003, 54, 806-817.	0.7	69
226	Effects of Sertraline on Sleep Architecture in Patients With Depression. Journal of Clinical Psychopharmacology, 2003, 23, 540-548.	0.7	63
227	Group Comparisons of DSM-IV Subtypes of Chronic Depression: Validity of the Distinctions, Part 2 Journal of Abnormal Psychology, 2003, 112, 614-622.	2.0	90
228	Psychosocial Outcomes Following Long-term, Double-blind Treatment of Chronic Depression With Sertraline vs Placebo. Archives of General Psychiatry, 2002, 59, 723.	13.8	77
229	Double-blind Switch Study of Imipramine or Sertraline Treatment of Antidepressant-Resistant Chronic Depression. Archives of General Psychiatry, 2002, 59, 233.	13.8	123
230	Sertraline versus imipramine to prevent relapse in chronic depression. Journal of Affective Disorders, 2001, 65, 27-36.	2.0	58
231	Efficacy of Mirtazapine for Prevention of Depressive Relapse. Journal of Clinical Psychiatry, 2001, 62, 782-788.	1.1	66
232	Comparison of DSM-III-R chronic major depression and major depression superimposed on dysthymia (double depression): Validity of the distinction Journal of Abnormal Psychology, 2000, 109, 419-427.	2.0	67
233	Venlafaxine and treatment-resistant depression. Depression and Anxiety, 2000, 12, 55-62.	2.0	33
234	Is cognitive behavior therapy just a †nonspecific†intervention for depression? A retrospective comparison of consecutive cohorts treated with cognitive behavior therapy or supportive counseling and pill placebo. Journal of Affective Disorders, 2000, 57, 63-71.	2.0	31

#	Article	IF	CITATIONS
235	Early- versus late-onset dysthymic disorder: comparison in out-patients with superimposed major depressive episodes. Journal of Affective Disorders, 1999, 52, 187-196.	2.0	52
236	Dysthymia: clinical picture, extent of overlap with chronic fatigue syndrome, neuropharmacological considerations, and new therapeutic vistas. Journal of Affective Disorders, 1999, 52, 275-290.	2.0	42
237	Age of onset in chronic major depression: relation to demographic and clinical variables, family history, and treatment response. Journal of Affective Disorders, 1999, 55, 149-157.	2.0	192
238	What To Do with SSRI Nonresponders?. Journal of Psychiatric Practice, 1999, 5, 216-223.	0.3	6
239	Vagus Nerve Stimulation. Epilepsia, 1998, 39, 677-686.	2.6	400
240	Workplace performance effects from chronic depression and its treatment. Journal of Health Economics, 1998, 17, 511-535.	1.3	167
241	Maintenance Phase Efficacy of Sertraline for Chronic Depression <subtitle>A Randomized Controlled Trial</subtitle> . JAMA - Journal of the American Medical Association, 1998, 280, 1665.	3.8	163
242	Predictors of Response to Acute Treatment of Chronic and Double Depression With Sertraline or Imipramine. Journal of Clinical Psychiatry, 1998, 59, 669-675.	1.1	107
243	Switching Strategies for the Treatment of Unipolar Major Depression. , 1997, 25, 56-65.		5
244	A prospective test of criteria for response, remission, relapse, recovery, and recurrence in depressed patients treated with cognitive behavior therapy. Journal of Affective Disorders, 1997, 43, 131-142.	2.0	65
245	Sleep-Onset Rapid Eye Movement Periods in Neuropsychiatric Disorders: Implications for the Pathophysiology of Psychosis. Journal of Nervous and Mental Disease, 1997, 185, 730-738.	0.5	30
246	Pharmacotherapy of Inpatients with Bipolar Depression. Annals of Clinical Psychiatry, 1997, 9, 199-202.	0.6	3
247	Pharmacotherapy of inpatients with bipolar depression. Annals of Clinical Psychiatry, 1997, 9, 199-202.	0.6	3
248	Hypothalamic-pituitary-adrenocortical activity and response to cognitive behavior therapy in unmedicated, hospitalized depressed patients. American Journal of Psychiatry, 1996, 153, 886-891.	4.0	80
249	Chlorpromazine and obsessive-compulsive symptoms. American Journal of Psychiatry, 1996, 153, 1503a-1503.	4.0	23
250	Efficacy of clomipramine in obsessive-compulsive disorder. Anxiety, 1996, 2, 56-57.	0.5	0
251	Induction of Mania With Serotonin Reuptake Inhibitors. Journal of Clinical Psychopharmacology, 1996, 16, 425-427.	0.7	86
252	The treatment of persons with dual diagnoses in a rural community. Psychiatric Quarterly, 1995, 66, 33-49.	1.1	14

#	Article	lF	CITATIONS
253	Biochemical Effects of Antidepressant Augmentation. Archives of General Psychiatry, 1995, 52, 156.	13.8	9
254	Thyroid function in mood disorders. Biological Psychiatry, 1995, 37, 63.	0.7	2
255	Psychopathology and mental retardation. American Journal of Psychiatry, 1995, 152, 1837-8.	4.0	1
256	The rarity of mania in Down's syndrome. British Journal of Psychiatry, 1994, 164, 422-422.	1.7	1
257	Selective serotonin reuptake inhibitors and mania. British Journal of Psychiatry, 1994, 165, 835-836.	1.7	3
258	The brainstem and psychosis. Biological Psychiatry, 1994, 35, 700.	0.7	0
259	Lithium-Induced Renal Dysfunction. Journal of Clinical Psychopharmacology, 1994, 14, 435.	0.7	1
260	Refractory Depression: Relevance of Psychosocial Factors and Therapies. Psychiatric Annals, 1994, 24, 232-240.	0.1	54
261	Bipolar Disorder Associated with Primary Generalised Epilepsy. British Journal of Psychiatry, 1993, 162, 699-700.	1.7	8
262	A Comprehensive Review of Cyclothymic Disorder. Journal of Nervous and Mental Disease, 1993, 181, 485-493.	0.5	52
263	General Health, Health Care Utilization, and Medical Comorbidity in Dysthymia. International Journal of Psychiatry in Medicine, 1993, 23, 211-238.	0.8	81
264	Chronic Depression. Psychiatric Services, 1993, 44, 633-639.	1.1	5
265	Thyroid dysfunction in refractory depression: implications for pathophysiology and treatment. Journal of Clinical Psychiatry, 1993, 54, 47-54.	1.1	77
266	Fluoxetine Treatment of Depression in Mentally Retarded Adults. Journal of Nervous and Mental Disease, 1992, 180, 202-205.	0.5	23
267	Biological studies of Dysthymia. Biological Psychiatry, 1991, 30, 283-304.	0.7	60
268	Lithium Augmentation of Fluoxetine in the Treatment of Ocd and Major Depression: a Case Report. Canadian Journal of Psychiatry, 1991, 36, 154-155.	0.9	8
269	Pharmacotherapy of Dysthymia. Journal of Clinical Psychopharmacology, 1991, 11, 83???92.	0.7	79
270	Barriers to Community Treatment of Patients With Dual Diagnoses. Psychiatric Services, 1990, 41, 1134-1135.	1.1	13

#	Article	IF	CITATIONS
271	Schizophrenia and amyotrophic lateral sclerosis. Comprehensive Psychiatry, 1990, 31, 327-336.	1.5	20
272	Treating Dual Diagnosis Patients: Challenges and Opportunities. Jefferson Journal of Psychiatry, 1990, 8, .	0.4	1
273	Markedly Increased Platelet Membrane Fluidity in Down Syndrome With a (14q, 21q) Translocation. Topics in Geriatrics, 1988, 1, 218-219.	0.9	5
274	PHARMACOTHERAPY FOR PSYCHOTIC DEPRESSION. Psychiatric Annals, 1985, 15, 506.	0.1	0
275	Therapeutic Armamentarium. , 0, , 861-875.		0